Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clinical immunosuppression. We report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolongedsurvival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants. CP-690,550 treatment was not associatedwith hypertension, hyperlipidemia, or lymphoproliferative disease. On the basis of these preclinical results, we believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation andin other clinical settings.

[1]  H. Stockinger,et al.  Suppression of early T-cell–receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154 , 2003, Transplantation.

[2]  M. Caligiuri,et al.  What does it take to make a natural killer? , 2003, Nature Reviews Immunology.

[3]  P. Stock.  The Year in Review – ATC 2002 , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  A. Sher,et al.  A Critical Role for IL-21 in Regulating Immunoglobulin Production , 2002, Science.

[5]  R. Fairchild,et al.  Chemokines: directing leukocyte infiltration into allografts. , 2002, Current opinion in immunology.

[6]  R. Morris,et al.  A life-supporting technique of renal allotransplantation in Macaca fascicularis to evaluate novel immunosuppressive drugs in nonhuman primates. , 2002, The Journal of surgical research.

[7]  T. Mueller,et al.  Analysis of the Innate and Adaptive Phases of Allograft Rejection by Cluster Analysis of Transcriptional Profiles1 , 2002, The Journal of Immunology.

[8]  F. Uckun,et al.  Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. , 2002, Blood.

[9]  G. Koretzky,et al.  Control of T Cell Function by Positive and Negative Regulators , 2002, Science.

[10]  Massimo Gadina,et al.  Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.

[11]  U. Christians,et al.  Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. , 2001, Transplantation.

[12]  R. Kirken,et al.  Concomitant Inhibition of Janus Kinase 3 and Calcineurin-Dependent Signaling Pathways Synergistically Prolongs the Survival of Rat Heart Allografts1 , 2001, The Journal of Immunology.

[13]  L. Berg,et al.  Cutting Edge: Two Distinct Mechanisms Lead to Impaired T Cell Homeostasis in Janus Kinase 3- and CTLA-4-Deficient Mice1 , 2001, The Journal of Immunology.

[14]  B. Kahan,et al.  Immunosuppressive agents in organ transplantation: past, present, and future. , 2000, Seminars in nephrology.

[15]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[16]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[17]  R. Perlmutter,et al.  Requirement for Jak3 in mature T cells: its role in regulation of T cell homeostasis. , 1998, Journal of immunology.

[18]  Robert A. Copeland,et al.  Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis , 1996 .

[19]  W. Leonard,et al.  Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.

[20]  J. Johnston,et al.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) , 1995, Nature.